LXRX Lexicon Pharmaceuticals, Inc.

-1  -6%
Previous Close 14.94
Open 14.87
Price To book 9.90
Market Cap 1.46B
Shares 104,319,000
Volume 1,069,864
Short Ratio 17.50
Av. Daily Volume 890,958

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial did not meet primary endpoint.
Type 1 Diabetes
Phase 3 data released September 9, 2016 met primary endpoint. Data from second trial released December 21, 2016 - primary endpoint met. Data from third trial due mid-2017.
Type 1 Diabetes
Approved February 28, 2017.
Telotristat etiprate (XERMELO)
Carcinoid Syndrome
Phase 3 trial initiated 4Q 2016.
Type 2 Diabetes

Latest News

  1. Lexicon Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : LXRX-US : March 20, 2017
  2. Surging Earnings Estimates Signal Good News for Lexicon (LXRX)
  4. Lexicon To Present At The Barclays Global Healthcare Conference
  5. Lexicon Pharmaceuticals, Inc. :LXRX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 7, 2017
  6. Lexicon To Present At The Cowen And Company 37th Annual Healthcare Conference
  7. LEXICON PHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report
  8. Edited Transcript of LXRX earnings conference call or presentation 3-Mar-17 3:00pm GMT
  9. Wedbush Has 3 Biotech Stocks to Buy With Massive Upside Potential
  10. Biotech Premarket Movers: Karyopharm, Lexicon, Prothena
  11. LEXICON PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
  12. Lexicon reports 4Q loss
  13. Lexicon reports 4Q loss
  14. Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2016 Fourth Quarter And Full Year Financial Results
  15. Biotech's Outlook Strengthens After President Trump's Speech: Today's Reports on Dynavax Technologies and Lexicon Pharmaceuticals
  16. Lexicon To Report Fourth Quarter And Year End 2016 Financial Results On March 3, 2017
  17. Here’s What’s Next For Lexicon Pharmaceuticals, Inc. (LXRX) And Dynavax Technologies Corporation (DVAX)
  18. Lexicon Stock Spikes 8% on Diarrhea Drug Approval
  19. UPDATE 1-FDA approves Lexicon Pharma's carcinoid syndrome diarrhea drug
  20. FDA approves Lexicon Pharma's carcinoid syndrome diarrhea drug